Effect of CoQ10 on the Outcome of MAFLD Patients
Effect of Coenzyme Q10 on the Outcome of Metabolic Dysfunction-Associated Fatty Liver Disease Patients
Ain Shams University
60 participants
Oct 31, 2023
INTERVENTIONAL
Conditions
Summary
So far there has been no universal treatment for MAFLD since it has a complex etiology that involves ethnic, genetic, metabolic and environmental factors. However, therapeutic life changes including: diet, weight loss, and physical activity remain the cornerstone of treatment and is recommended by both American and European associations. Inflammatory biomarkers, such as tumor necrosis factor-alpha, and adipokines play key roles in the pathogenesis of MAFLD, hence, the anti-inflammatory and antioxidant effects of coenzyme Q10 especially at high doses that have not been tested are hypothesized to have a beneficial role in improving the systemic inflammation and biochemical variables. This study is conducted to test this hypothesis
Eligibility
Inclusion Criteria13
- All study subjects and prior to consenting to the ICF, laboratory and imaging work-up will be evaluated for the presence of three out of five criteria for metabolic dysregulation in the context of metabolic -dysfunction associated fatty liver disease (MAFLD):
- Waist circumference (WC) ≥ 102/88 cm for men and women respectively.
- HDL cholesterol <40 mg/dl in men and <50 mg/dl in women or on specific drug therapy.
- Plasma Triglycerides ≥ 150 mg/dl or on specific drug therapy.
- Blood pressure ≥130 and/or ≥ 85 or on specific anti-hypertensive therapy.
- Fasting blood glucose ≥ 100 mg/dl or on specific anti hyperglycemic therapy
- Patients who agree to sign an informed consent
- Adult patients >18 years old.
- Males and females
- Willing to comply with procedures and follow up
- Elevated serum transaminases (1-4 times the ULN)
- Imaging evidence of fatty liver:
- pelviabdominal ultrasound and Fibro- CAP study
Exclusion Criteria18
- Pregnancy or lactating
- Physical or mental abnormalities
- HCV infection
- HBV infection
- Anaemia
- Thrombocytopenia
- Haematological malignancies
- Ongoing alcoholism (Male: >30g/day, Female: >20g/day)
- Patients with renal failure
- Autoimmune hepatitis
- Celiac disease
- Wilson's disease
- Hemochromatosis
- Drugs: Tamoxifen, Valproic acid, Amiodarone, Methotrexate, Steroids, Anticoagulants, All anti-oxidative stress agents, Cos, IUD
- Chronic use of systematically immunosuppressive agent or drugs that can affect liver profile.
- Hypo/Hyper-thyroidism
- Bypass surgeries
- TPN (Total Parenteral Nutrition)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Coenzyme Q10 in the form of soft gelatin capsules, each capsule containing 100 mg
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05984745